Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts said.

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert ...

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

seed funding round. The financing was led by Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional ...

Compared to 2021, funding for biotech and pharmaceuticals ... beating its benchmark by 208 percentage points (see more details here). Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company ...

For Pfizer Inc., the strategy has been “go big ... by a change in the US presidency and anticipated cuts in government funding for biopharma research. Conspiracy theories in the US around ...

NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has left the door open for negotiations if the pharma decides to drop its price.

Biotech companies are further pushed into making these deals due to the drying up of venture funding in China. Despite varying opinions among experts, there is an industry-wide consensus that this ...